Clinical Trials Browser

Cholangiocarcinoma × Cisplatin × 1 year × Clear all

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06607185 2026-04-22

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05967182 2026-04-16

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

24 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Phase 1 Recruiting

12 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

757 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2 Recruiting

33 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT03768414 2026-01-12

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Phase 3 Completed

452 enrolled 17 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06546969 2025-12-10

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Phase 1 Recruiting

15 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06440993 2025-12-01

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Phase 2 Recruiting

42 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03656536 2025-08-24

FIGHT-302

Phase 3 Terminated

167 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT03579771 2025-08-15

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Phase 2 Completed

30 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02375880 2025-08-03

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Phase 1 Completed

51 enrolled

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

62 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Not yet recruiting

38 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05712356 2025-06-06

BOLSTER

Phase 2 Active not recruiting

67 enrolled

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

Clinical Trials

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

KEYNOTE-966

KEYNOTE-966

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

FIGHT-302

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

KEYVIBE-005

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

SAIB

BOLSTER